SG11202008820WA - Compositions and methods for evaluating attenuation and infectivity of listeria strains - Google Patents

Compositions and methods for evaluating attenuation and infectivity of listeria strains

Info

Publication number
SG11202008820WA
SG11202008820WA SG11202008820WA SG11202008820WA SG11202008820WA SG 11202008820W A SG11202008820W A SG 11202008820WA SG 11202008820W A SG11202008820W A SG 11202008820WA SG 11202008820W A SG11202008820W A SG 11202008820WA SG 11202008820W A SG11202008820W A SG 11202008820WA
Authority
SG
Singapore
Prior art keywords
infectivity
compositions
methods
listeria strains
evaluating attenuation
Prior art date
Application number
SG11202008820WA
Inventor
Poonam Molli
Anu Wallecha
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of SG11202008820WA publication Critical patent/SG11202008820WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
SG11202008820WA 2018-03-09 2019-03-08 Compositions and methods for evaluating attenuation and infectivity of listeria strains SG11202008820WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640855P 2018-03-09 2018-03-09
PCT/US2019/021303 WO2019173684A1 (en) 2018-03-09 2019-03-08 Compositions and methods for evaluating attenuation and infectivity of listeria strains

Publications (1)

Publication Number Publication Date
SG11202008820WA true SG11202008820WA (en) 2020-10-29

Family

ID=66102746

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008820WA SG11202008820WA (en) 2018-03-09 2019-03-08 Compositions and methods for evaluating attenuation and infectivity of listeria strains

Country Status (11)

Country Link
US (1) US20210003558A1 (en)
EP (1) EP3762719A1 (en)
JP (2) JP2021516972A (en)
KR (1) KR20200130399A (en)
CN (1) CN112074737A (en)
AU (1) AU2019231783B2 (en)
CA (1) CA3093467C (en)
IL (1) IL277255A (en)
MX (1) MX2020009405A (en)
SG (1) SG11202008820WA (en)
WO (1) WO2019173684A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
JP7197481B2 (en) 2016-11-30 2022-12-27 アドバクシス， インコーポレイテッド Immunogenic compositions targeting recurrent cancer mutations and methods of their use
MX2020003100A (en) 2017-09-19 2020-08-20 Advaxis Inc COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR <i>LISTERIA </i>STRAINS.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
IL151942A0 (en) 2000-03-29 2003-04-10 Univ Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
EP1513924A4 (en) 2002-05-29 2008-05-21 Univ California Attenuated listeria spp. and methods for using the same
AU2004246999B2 (en) 2003-02-06 2010-06-10 Aduro Biotech, Inc., Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US7665238B2 (en) 2006-04-03 2010-02-23 S.C. Johnson & Son, Inc. Air freshener with holder
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
PE20190844A1 (en) 2012-05-25 2019-06-17 Emmanuelle Charpentier MODULATION OF TRANSCRIPTION WITH ADDRESSING RNA TO GENERIC DNA
CA2888727A1 (en) 2012-12-27 2014-07-03 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
JP7009061B2 (en) * 2014-04-24 2022-01-25 アドバクシス， インコーポレイテッド Recombinant Listeria vaccine strain and method for producing it
WO2016011353A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
MA41218A (en) * 2014-12-19 2017-10-24 Advaxis Inc LISTERIA VACCINE COMBINATION WITH ANTI-OX40 OR ANTI-GITR ANTIBODIES
US20170204361A1 (en) * 2015-06-24 2017-07-20 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
MA42841A (en) * 2015-09-15 2018-07-25 Advaxis Inc METHOD OF MANUFACTURING AN IMMUNOTHERAPEUTIC FORMULATION INCLUDING A RECOMBINATION LISTERIA STRAIN
AR110730A1 (en) * 2017-01-05 2019-04-24 Advaxis Inc LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY

Also Published As

Publication number Publication date
CA3093467A1 (en) 2019-09-12
IL277255A (en) 2020-10-29
EP3762719A1 (en) 2021-01-13
WO2019173684A1 (en) 2019-09-12
AU2019231783A1 (en) 2020-10-08
KR20200130399A (en) 2020-11-18
JP2021516972A (en) 2021-07-15
CA3093467C (en) 2022-12-06
CN112074737A (en) 2020-12-11
MX2020009405A (en) 2021-01-08
JP2023168614A (en) 2023-11-24
AU2019231783B2 (en) 2023-11-16
US20210003558A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
IL277255A (en) Compositions and methods for evaluating attenuation and infectivity of listeria strains
GB2614634B (en) Cannabinoid compositions and methods of using
IL273255A (en) Compositions and methods for lyophilization of bacteria or listeria strains
GB202007991D0 (en) CAS12C Compositions and methods of use
EP3108245A4 (en) Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EP4034253A4 (en) Compositions and methods for increasing the efficacy of immunotherapies and vaccines
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL285117A (en) Methods of characterizing condensate-associated characteristics of compounds and uses thereof
IL288091A (en) Methods of characterizing and utilizing agent-condensate interactions
SG11202011274YA (en) Chemical compositions and methods of using same
ZA202004531B (en) Compositions containing thymohydroquinone and their method of preparation
HK1250345A1 (en) Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
SG11202104207TA (en) Oligosaccharide compositions and methods of use thereof
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
EP3759505C0 (en) Method for evaluating the state and the quality of low-voltage networks
IL287797A (en) Oligosaccharide compositions and methods of use
IL286580A (en) Compositions and methods for the stabilization of micro-rna
IL290325A (en) Biopharmacuetical compositions and related methods
IL286704A (en) Probiotic biofilm compositions and methods of preparing same
GB201919385D0 (en) Compositions and methods of manufacture
EP4081047A4 (en) Enzyme compositions and methods of making them
SG11202108262VA (en) Bacterialcidal methods and compositions
EP3968994C0 (en) Abhd12 inhibitors and methods of making and using same
EP3941382A4 (en) Cleaning indicator and method of using same